MedTrace Logo

Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates

NCT03478774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2021-02-03

No results posted yet for this study

Summary

This study compares under controlled conditions if different flow rates affect apnoea time after induction of anaesthesia and how CO2 clearance is influenced. Furthermore, this study enables to quantify the effects of increased pCO2 on vital parameters (e.g. blood pressure, cardiac output, cerebral perfusion, etc.) The investigators will enroll patients undergoing elective surgery at the University Hospital of Bern, Switzerland.

Once anesthesia has been induced, apnoea will set it. During this period, the investigators will compare different methods of apnoeic oxygenation for a maximum of 15 or 30 minutes.

Before discharge, an interview will be conducted, assessing complications and patient satisfaction.

Conditions

  • Apnoeic Oxygenation

Interventions

DRUG

Oxygen 70l/min

HFNCT will be provided using OptiFlow by Fisher\&Paykel.

DRUG

Oxygen 10 l/min

Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

DRUG

Oxygen 2l/min

Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

PROCEDURE

Jaw thrust

Continuous

PROCEDURE

Videolaryngoscopy

Continuous

DRUG

oxygen 0.25l/min

0.25l/min of oxygen via an endotracheal tube

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Lorenz Theiler, PD MD · University hospital of Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-25
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478774 on ClinicalTrials.gov